相关实验视频

Updated: Jun 23, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

生物标志物驱动的个性化免疫预防:朝着更有效的临床试验?

Sai Yendamuri¹, Konstantin H Dragnev²

¹Department of Thoracic Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Cancer prevention research (Philadelphia, Pa.)

|June 17, 2024

概括

患有克隆性血液形成突变的患者,特别是TET2基因的患者,可能会从抗干素-1β药物canakinumab中受益,经历癌症风险降低. 这表明个性化癌症预防策略可以提高试验可行性.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
免疫学免疫学免疫学

背景情况:

克隆性血液形成 (CH) 与炎症和癌症风险增加有关.
介素-1β (IL-1β) 是一种关键的炎症性细胞因子,与癌症发展有关.
在CANTOS试验中,评估了抗IL-1β单克隆抗体canakinumab,用于降低心血管风险.

研究的目的:

为了研究克隆性血液形成突变与与canakinumab治疗减少癌症风险之间的关联.
探索针对IL-1β的潜力,以在CH患者中进行个性化癌症化学预防.

主要方法:

来自CANTOS随机对照试验的患者样本的二次分析.
周围血液DNA的基因定型,以确定克隆性血液形成突变,重点是TET2.
评估癌症发病率与canakinumab治疗和CH突变存在的关系.

主要成果:

患有克隆性血液形成突变,特别是TET2突变的患者在接受canakinumab治疗时,癌症风险显著降低.
在降低癌症风险方面,CH突变的存在预测了对抗IL-1β治疗的有益反应.
虽然数量很小,但研究结果表明,可纳基努马布在预防癌症中的有效性是潜在的生物标志物.

结论:

克隆造血突变,特别是在TET2中,可能会识别出受益于canakinumab降低癌症风险的患者.
这些发现支持基于遗传特征的个性化化疗预防策略的开发.
个性化方法可以提高未来癌症预防试验的设计和可行性.

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.